Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies
Objective: To report the safety, tolerability, and pharmacokinetics/pharmacodynamics (PK/PD) of eptinezumab using intravenous (IV) infusion compared to other routes of administration from two phase 1 trials. Methods: Study 1 (NCT01579383) and Study 2 (ACTRN12615000531516) were double-blind, placebo-...
Main Authors: | Brian Baker, Vivienne Shen, Roger Cady, Anders Ettrup, Frank Larsen |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-10-01
|
Series: | Cephalalgia Reports |
Online Access: | https://doi.org/10.1177/25158163221131326 |
Similar Items
-
Corrigendum to “Eptinezumab administered intravenously, subcutaneously, or intramuscularly in healthy subjects and/or patients with migraine: Early development studies”
Published: (2024-03-01) -
Shift in diagnostic classification of migraine after initiation of preventive treatment with eptinezumab: post hoc analysis of the PROMISE studies
by: Patricia Pozo-Rosich, et al.
Published: (2022-10-01) -
Optimization of acute medication use following eptinezumab initiation during a migraine attack: post hoc analysis of the RELIEF study
by: Roger Cady, et al.
Published: (2022-07-01) -
Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2022-06-01) -
Correction: Rapid resolution of migraine symptoms after initiating the preventive treatment eptinezumab during a migraine attack: results from the randomized RELIEF trial
by: Jessica Ailani, et al.
Published: (2023-09-01)